Pharmacological treatment of overactive bladder: the potential of anticholinergic therapy

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The management of overactive bladder (OAB) involves drugs from several pharmacological classes, among which anticholinergic agents occupy an important place. The choice of therapy should be strictly individualized, taking into account not only the expected efficacy but also potential drug interactions, age-related pharmacokinetic and pharmacodynamic changes, comorbidities, the overall anticholinergic burden, and the risk of adverse effects.

Trospium chloride (Spasmex) is considered the drug of choice for patients with OAB. Its pharmacological properties ensure both clinical efficacy and good tolerability, along with proven cognitive safety. Trospium chloride does not cross the blood–brain barrier and therefore does not cause central nervous system adverse effects. Another advantage of trospium chloride is the flexible dosing regimen, which allows for individualized dose titration according to patient response and tolerability.

全文:

受限制的访问

作者简介

Igor Kuzmin

Pavlov First Saint Petersburg State Medical University, Ministry of Health of the Russian Federation

编辑信件的主要联系方式.
Email: kuzminigor@mail.ru
ORCID iD: 0000-0002-7724-7832
SPIN 代码: 2684-4070

Ph.D., MD, professor, Department of Urology

俄罗斯联邦, Saint Petersburg

参考

  1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P et al. The standartisation of terminology in lower urinary tract function: Report from the standartisation sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-178. https://doi.org/10.1002/nau.10052
  2. Kuzmin IV. Pathogenesis, clinical course and treatment of overactive bladder [dissertation]. Saint Petersburg, 2007. EDN: QECRJB. Russian (Кузьмин И.В. Патогенез, клиническое течение и лечение гиперактивности мочевого пузыря: Дис. … докт. мед. наук. СПб., 2007).
  3. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306-1314. https://doi.org/10.1016/j.eururo.2006.09.0193
  4. Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87(9):760-766. https://doi.org/10.1046/j.1464-410X.2001.02228.x EDN: BACBIR
  5. Kuzmin IV. Epidemiological aspects of overactive bladder and urge urinary incontinence. Urologicheskie vedomosti. 2015;5(3):30–34. https://doi.org/10.17816/uroved5330-3 EDN: VHUCCH. Russian (Кузьмин И.В. Эпидемиологические аспекты гиперактивного мочевого пузыря и ургентного недержания мочи. Урологические ведомости. 2015;5(3): 30–34).
  6. Kuzmin IV. Assessment of the quality of life in patients with overactive bladder. Nefrologiya = Nephrology (Saint-Petersburg). 2006;10(4):93–97. EDN: JURDFP. Russian (Кузьмин И.В. Оценка качества жизни у больных с гиперактивностью мочевого пузыря. Нефрология. 2006;10(4):93–97).
  7. Peyronnet B, Mironska E, Chapple C, Cardozo L, Oelke M et al. A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment. Eur Urol. 2019;75(6):988-1000. https://doi.org/10.1016/j.eururo.2019.02.038
  8. Kushida N, Fry CH. On the origin of spontaneous activity in the bladder. BJU Int. 2016;117(6):982-992. https://doi.org/10.1111/bju.13240
  9. Thurmond P, Yang JH, Azadzoi KM. LUTS in pelvic ischemia: a new concept in voiding dysfunction. Am J Physiol Renal Physiol. 2016;310(8):F738-F743 https://doi.org/10.1152/ajprenal.00333.201521
  10. Al-Shukri SH, Kuz’min IV, Amdiy RE, Boriskin AG, Slesarevskaya MN, Lukina EE Microcirculation in urinary bladder wall and clinical symptoms of overactive bladder in women. Experimental and Clinical Urology. 2010;(2):52–55 EDN: OREORX. Russian (Аль-Шукри С.Х., Кузьмин И.В., Амдий Р.Э., Борискин А.Г., Слесаревская М.Н., Лукина Е.Е. Состояние микроциркуляции в стенке мочевого пузыря и клинические проявления гиперактивности мочевого пузыря у женщин. Экспериментальная и клиническая урология. 2010;2:52–55).
  11. Al-Shukri SH, Kuzmin IV, Boriskin AG, Slesarevskaya MN, Kyrkunova SL. Correction of microcirculatory disorders in patients with overactive bladder. Nefrologiya = Nephrology (Saint-Petersburg). 2011;15(1):58–64. Russian (Аль-Шукри С.Х., Кузьмин И.В., Борискин А.Г., Слесаревская М.Н., Кыркунова С.Л. Коррекция нарушений микроциркуляции у больных с гиперактивностью мочевого пузыря. Нефрология. 2011;15(1):58–64). EDN: NUDVJN
  12. Shormanov IS, Kulikov SV, Solovyov AS. Features of compensatory and adaptive reactions of the vascular bed of the bladder of elderly and senile men with prostatic hyperplasia. Urology reports (St-Petersburg). 2022;12(2):127-35. https://doi.org/10.17816/uroved108475 EDN: WNTMZA. Russian (Шорманов И.С., Куликов С.В., Соловьев А.С. Особенности компенсаторно-адаптационных реакций сосудистого русла мочевого пузыря мужчин пожилого и старческого возраста в условиях гиперплазии предстательной железы. Урологические ведомости. 2022;12(2):127–135).
  13. Urinary incontinence. Clinical recommendations of the Ministry of Health of the Russian Federation. 2024. Available via the link: https://cr.minzdrav.gov.ru/view-cr/8_2 Date of access: 08/19/2025). Russian (Недержание мочи. Клинические рекомендации Минздрава РФ. 2024. Доступно по ссылке: https://cr.minzdrav.gov.ru/view-cr/8_2 Дата доступа 19.08.2025).
  14. Management of non-neurogenic female lower urinary tract symptoms (LUTS). EAU Guideline / C.K. Harding, M.C. Lapitan, S. Arlandis, K. Bø, H. Cobussen-Boekhorst, et al. European Association of Urology. 2025. Доступно по ссылке: https://uroweb.org/guidelines/non-neurogenic-female-luts. Дата доступа: 19.08.2025.
  15. Alyayev Yu.G., Gadzhieva Z.K. M-Cholinoblockers in the Treatment of an Overactive Bladder. Effective Pharmacotherapy. 2010;29:28–35. Russian (Аляев Ю.Г., Гаджиева З.К. М-холиноблокаторы в лечении гиперактивного мочевого пузыря. Эффективная фармакотерапия. 2010;29:28–35).
  16. Kulchavenya EV, Kholtobin DP. Overactive bladder in a complicated patient: which drug to choose? Urologiia. 2021;(1):120–125 https://doi.org/10.18565/urology.2021.1.120-125 EDN: XCGKDU. Russian (Кульчавеня Е.В., Холтобин Д.П. Гиперактивный мочевой пузырь у сложного пациента: какой препарат выбрать? Урология. 2021;(1):120–125).
  17. Kuzmin IV Personalized approach to pharmacotherapy of overactive bladder. Urology reports (St.-Petersburg). 2023;13(3):267–282 https://doi.org/10.17816/uroved569404 EDN: XJVYUG. Russian (Кузьмин И.В. Персонифицированный подход к фармакотерапии гиперактивного мочевого пузыря. Урологические ведомости. 2023;13(3):267–282).
  18. Kuzmin IV, Kuzmina SV. Anticholinergic therapy of an overactive bladder: clinical practice aspects. Russian Medical Inquiry. 2021;5(5):273–279. https://doi.org/10.32364/2587-6821-2021-5-5-273-279 EDN: WABDWM. Russian (Кузьмин И.В., Кузьмина С.В. Антихолинергическая терапия гиперактивного мочевого пузыря: практические аспекты. РМЖ. Медицинское обозрение. 2021;5(5):273–279).
  19. Kerdraon J, Robain G, Jeandel C et al. Impact on cognitive function of anticholinergic drugs used for the treatment of overactive bladder in the elderly. Prog Urol. 2014;24(11):672-681. https://doi.org/10.1016/j.purol.2014.06.003
  20. Kuzmin IV, Slesarevskaya MN. Anticholinergic bladder therapy: geriatric aspects. Clin Gerontol. 2021;27(11-12):21–34. (In Russian)] https://doi.org/10.26347/1607-2499202111-12021-034 EDN: ZHMMTR Russian (Кузьмин И.В., Слесаревская М.Н. Антихолинергическая терапия гиперактивного мочевого пузыря: геронтологические аспекты. Клиническая геронтология. 2021;27(11-12):21–34).
  21. Zinner NR. Trospium chloride: an anticholinergic quaternary ammonium compound for the treatment of overactive bladder. Expert Opin Pharmacother. 2005;6(8):1409-20. https://doi.org/10.1517/14656566.6.8.1409
  22. Truzzi JC, Sartori MGF, Kemp VL. Trospium Chloride in the Treatment of Overactive Bladder Syndrome and Detrusor Overactivity. Adv Ther. 2025 Jul 3. https://doi.org/10.1007/s12325-025-03275-8
  23. Rovner ES. Trospium chloride in the management of overactive bladder. Drugs. 2004;64(21):2433–4246. https://doi.org/10.2165/00003495-200464210-00005 EDN: GGBUVU
  24. Guay DR. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet. 2003;42(14):1243–1285. https://doi.org/10.2165/00003088-200342140-00004 EDN: GYLHHS
  25. Doroshyenko O, Jetter A, Odenthal KP, Fuhr U. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet. 2005;44(7):701–720. https://doi.org/10.2165/00003088-200544070-00003 EDN: LQPZWS
  26. Staskin DR. Trospium chloride: Distinct among other anticholinergic agents available for the treatment of overactive bladder. Urol Clin North Am. 2006;33(4):465-473. https://doi.org/10.1016/j.ucl.2006.06.006
  27. Dahlinger D, Aslan S, Pietsch M, Frechen S, Fuhr U. Assessment of inhibitory effects on major human cytochrome P450 enzymes by spasmolytics used in the treatment of overactive bladder syndrome. Ther Adv Urol. 2017;9(7):163–177. https://doi.org/10.1177/1756287217708951
  28. Manikandan P, Nagini S. Cytochrome P450 Structure, Function and Clinical Significance: A Review. Curr Drug Targets. 2018;19(1):38-54. https://doi.org/10.2174/138945011866617012514455
  29. Cardozo L, Chapple CR, Toozs-Hobson P, Grosse-Freese M, Bulitta M et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial. BJU Int. 2000;85(6):659-664. https://doi.org/10.1046/j.1464-410x.2000.00575.x
  30. Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology. 2006;67(2):275-280. https://doi.org/10.1016/j.urology.2005.08.01
  31. Halaska M, Ralph G, Wiedemann A, Primus G, Ballering-Brühl B et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol. 2003;20(6):392-399. https://doi.org/ 10.1007/s00345-003-0321-8 EDN: ESLBOT
  32. Pushkar DYu, Schaveleva ОВ. Spasmex treatment of patients with hyperactive urinary bladder. Urologiia. 2003;(4):46–49. EDN: OKLCRZ. Russian (Пушкарь Д.Ю., Щавелева О.Б. Спазмекс в лечении больных с гиперактивным мочевым пузырем. Урология. 2003;4:46–49).
  33. Mazo EB, Krivoborodov GG, Shkolnikov ME, Babanina GA, Kozyrev SV, Korshunova ES. Trospium chloride in the treatment of idiopathic and neurogenic detrusor overactivity. Urologiia. 2005;(4):56-59. EDN: OKLGFX. Russian (Мазо Е.Б., Кривобородов Г.Г., Школьников М.Е., Бабанина Г.А., Козырев С.В., Коршунова Е.С. Троспиум хлорид в лечении идиопатической и нейрогенной детрузорной гиперактивности. Урология. 2005;4:56–59).
  34. Krivoborodov GG, Tkacheva ON, Efremov NS, Shyrin DA, Gontar AA. Trospium chloride in older patients with idiopathic overactive urinary badder. Russian Journal of Geriatric Medicine. 2022;1(9):58–63. https://doi.org/10.37586/2686-8636-1-2022-58-63 EDN: NPYNCU. Russian (Кривобородов Г.Г., Ткачева О.Н., Ефремов Н.С., Ширин Д.А., Гонтарь А.А. Троспия хлорид у больных пожилого возраста с идиопатическим гиперактивным мочевым пузырем. Российский журнал гериатрической медицины. 2022;1(9):58–63).
  35. Kulchavenya EV, Treyvish LS, Baranchukova AA. Charasteristics of the treatment of urinary disorders in postmenopausal women. Urologiia. 2021;(6):72–77. https://doi.org/10.18565/Urology.2021.6.72-77 EDN: KOLLIT. Russian (Кульчавеня Е.В., Трейвиш Л.С., Баранчукова А.А. Особенности лечения нарушений мочеиспускания у женщин в постменопаузе. Урология. 2021;6:72–77).
  36. Stöhrer M, Bauer P, Giannetti BM, Richter R, Burgdörfer H, Mürtz G. Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. A multicentre placebo-controlled double-blind trial. Urol Int. 1991;47(3):138–43. https://doi.org/10.1159/000282207
  37. Menarini M, Del Popolo G, Di Benedetto P, Haselmann J, Bödeker RH et al. Trospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients? Int J Clin Pharmacol Ther. 2006;44(12):623–632. https://doi.org/10.5414/cpp44623 EDN: MHSMSH
  38. Bödeker RH, Madersbacher H, Neumeister C, Zellner M. Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence. BMC Urol. 2010;10:15. https://doi.org/10.1186/1471-2490-10-15
  39. Krivoborodov GG, Tur EI, Efremov NS, Shkolnikov ME. High doses of trospium chloride in patients with overactive bladder due to neurologic disease. The multicenter observational program RESOURCE. Consilium Medicum. 2015;17(12):64–67. https://doi.org/10.26442/2075-1753_2015.12.64-67 EDN: VIMUTT. Russian (Кривобородов Г.Г., Тур Е.И., Ефремов Н.С., Школьников М.Е. Высокие дозы троспия хлорида у больных гиперактивным мочевым пузырем вследствие неврологических заболеваний. Данные мультицентровой наблюдательной программы РЕСУРС. Consilium Medicum. 2015;17(12):64–67).
  40. Krivoborodov GG, Tur EI, Efremov NS. Trospium chloride in the treatment of overactive bladder in elderly patients with neurological diseases (data multicenter observational program RESOURCE). Consilium Medicum. 2016;18 (7):55–59.. https://doi.org/10.26442/2075-1753_2016.7.55-59 EDN: XAAAND. Russian (Кривобородов Г.Г., Тур Е.И., Ефремов Н.С. Троспия хлорид в лечении гиперактивного мочевого пузыря у пациентов пожилого и старческого возраста с неврологическими заболеваниями (данные многоцентровой наблюдательной программы РЕСУРС. Consilium Medicum. 2016;18(7):55–59).
  41. Korshunova ES, Andreev MN, Korshunov MN, Pyatnitskaya TM, Korshunov DM et al. Long-term safety and efficacy of trospium chloride for the treatment of neurogenic overactive bladder due to Parkinson’s disease – is there an effect on cognitive status? Urologiia. 2022;(6):71–77. https://doi.org/10.18565/urology.2022.6.71-77 EDN: BYRGTV. Russian (Коршунова Е.С., Андреев М.Н., Коршунов М.Н., Пятницкая Т.М., Коршунов Д.М., и др. Долгосрочная безопасность и эффективность троспия хлорида при лечении нейрогенного гиперактивного мочевого пузыря вследствие болезни Паркинсона – есть ли влияние на когнитивный статус? Урология. 2022;6:71–77).
  42. Stoniute A, Madhuvrata P, Still M, Barron-Millar E, Nabi G, Omar MI. Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2023;5(5):CD003781. https://doi.org/10.1002/14651858.CD003781.pub3 EDN: RVUPTM
  43. McFerren SC, Gomelsky A. Treatment of Overactive Bladder in the Elderly Female: The Case for Trospium, Oxybutynin, Fesoterodine and Darifenacin. Drugs Aging. 2015;32(10):809–819. https://doi.org/10.1007/s40266-015-0301-x EDN: QRLJMM
  44. Zeevi N, Pachter J, McCullough LD, Wolfson L, Kuchel GA. The blood-brain barrier: geriatric relevance of a critical brain-body interface. J Am Geriatr Soc. 2010;58(9):1749–1757. doi: 10.1111/j.1532-5415.2010.03011.x
  45. Welk B, Richardson K, Panicker JN. The cognitive effect of anticholinergics for patients with overactive bladder. Nat Rev Urol. 2021;18(11):686–700. https://doi.org/10.1038/s41585-021-00504-x EDN: HXEXLP
  46. Welk B. The impact of anticholinergics on cognitive function in patients with neurogenic lower urinary tract dysfunction: A narrative review. Indian J Urol. 2024;40(2):82–87. https://doi.org/10.4103/iju.iju_352_23 EDN: DKUEYR
  47. Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–407. doi: 10.1001/jamainternmed.2014.7663 EDN:UUNAUV
  48. Pieper NT, Grossi CM, Chan WY, Loke YK, Savva GM et al. Anticholinergic drugs and incident dementia, mild cognitive impairment and cognitive decline: a meta-analysis. Age Ageing. 2020;49(6):939–947. https://doi.org/10.1093/ageing/afaa090 EDN: HVLNPS
  49. Heesakkers J., Espuña Pons M., Toozs Hobson P., Chartier-Kastler E. Dealing with complex overactive bladder syndrome patient profiles with focus on fesoterodine: in or out of the EAU guidelines? Res Rep Urol. 2017;9:209–218. https://doi.org/10.2147/RRU.S146746
  50. Madersbacher H, Rovner E. Trospium chloride: the European experience. Expert Opin Pharmacother. 2006;7(10):1373–1380. https://doi.org/10.1517/14656566.7.10.1373
  51. Kranz J, Petzinger E, Geyer J. Brain penetration of the OAB drug trospium chloride is not increased in aged mice. World J Urol. 2013;31(1):219–224. doi: 10.1007/s00345-011-0803-z EDN: XNGBUK
  52. Staskin D, Kay G, Tannenbaum C, Goldman HB, Bhashi K et al. Trospium chloride is undetectable in the older human central nervous system. J Am Geriatr Soc. 2010;58(8):1618–1619. https://doi.org/10.1111/j.1532-5415.2010.02988.x
  53. Naseri A, Sadigh-Eteghad S, Seyedi-Sahebari S, Hosseini MS, Hajebrahimi S, Salehi-Pourmehr H. Cognitive effects of individual anticholinergic drugs: a systematic review and meta-analysis. Dement Neuropsychol. 2023;17:e20220053. https://doi.org/10.1590/1980-5764-DN-2022-0053 EDN: NYRIQN
  54. Geller EJ, Dumond JB, Bowling JM, Khandelwal CM, Wu JM et al. Effect of Trospium Chloride on Cognitive Function in Women Aged 50 and Older: A Randomized Trial. Female Pelvic Med Reconstr Surg. 2017;23(2):118-123. https://doi.org/10.1097/SPV.0000000000000374
  55. Huang SW, Wang WT, Chou LC, Liou TH, Lin HW. Risk of Dementia in Patients with Spinal Cord Injury: A Nationwide Population-Based Cohort Study. J Neurotrauma. 2017;34(3):615–622. https://doi.org/10.1089/neu.2016.4525
  56. Amato MP, Zipoli V, Portaccio E. Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies. J Neurol Sci. 2006;245(1-2):41–46. https://doi.org/10.1016/j.jns.2005.08.019
  57. Korshunova ES, Korshunov MN, Nuzhnyi EP, Zakroyshсhikova IV, Zabirova AKh et al. Neurogenic overactive bladder: focus on cognitive function. Urologiia. 2021;(5):35–40. https://doi.org/10.18565/urology.2021.5.35-40 EDN: AXPPZP. Russian (Коршунова Е.С., Коршунов М.Н., Нужный Е.П., Закройщикова И.В., Забирова А.Х., и др. Нейрогенный гиперактивный мочевой пузырь: фокус на когнитивную функцию. Урология. 2021;5:35–40).
  58. Kulchavenya EV, Shevchenko SYu. Impact of the SARS-COV-2 virus on the urinary bladder. Urologiia. 2023;(1):41–45. https://doi.org/10.18565/urology.2023.1.41-45 EDN: JUSUGC. Russian (Кульчавеня Е.В., Шевченко С.Ю. Влияние вируса SARS-CoV-2 на мочевой пузырь. Урология. 2023;1:41–45).
  59. Kulchavenya EV. Post-COVID syndrome in urology. Clinical review for general practice. 2022;(4):66–72.. https://doi.org/10.47407/kr2022.3.4.00154 EDN: GEELUA. Russian (Кульчавеня Е.В. Постковидный синдром в урологии. Клинический разбор в общей медицине. 2022;4:66–72).

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2025